Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
(Thomson Reuters ONE) -
Basilea Pharmaceutica AG /
Basilea shareholders approve all resolutions proposed by the Board of Directors
at the Ordinary General Meeting of Shareholders
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Basel, Switzerland, April 27, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN)
reported that at today's Ordinary General Meeting of Shareholders for the
financial year 2016, shareholders approved all agenda items proposed by the
Board of Directors.
The shareholders approved the annual report, the financial statements, and
consolidated financial statements for the business year 2016, and approved the
release of the members of Basilea's Board of Directors and Management Committee.
Shareholders also approved carrying forward the accumulated deficit, and re-
elected PricewaterhouseCoopers AG, Basel as Statutory Auditors for the audit of
the stand-alone and consolidated financial statements for the business year
2017.
The shareholders elected Dr. Nicole Onetto as a new member of Basilea's Board of
directors and re-elected Domenico Scala as Chairman and Prof. Daniel Lew, Dr.
Martin Nicklasson, Dr. Thomas M. Rinderknecht, Steven D. Skolsky and Dr. Thomas
Werner as members of the Board of Directors. The shareholders also re-elected
Dr. Nicklasson, Mr. Skolsky and Dr. Werner as members of the Compensation
Committee. Dr. Caroline Cron was re-elected as Independent Voting Rights
Representative. The terms of all these individuals last until the end of the
2018 Ordinary General Meeting of Shareholders.
"I am delighted that Nicole Onetto has been elected as a new member of the Board
of Directors," said Domenico Scala, Chairman of the Board of Directors. "Her
wealth of experience both operationally and strategically in developing and
bringing innovative oncology drugs to patients will further strengthen the
Board's oncology expertise."
The shareholders also approved the increase of the authorized share capital.
Finally, the shareholders approved the proposed maximum aggregate amount of the
compensation for the Board of Directors for the period until the 2018 Ordinary
General Meeting, the maximum aggregate amount of fixed compensation for the
Management Committee for the period of July 1, 2017 to June 30, 2018, and the
maximum aggregate amount of variable compensation for the Management Committee
for the period from January 1, 2017 to December 31, 2017. In a non-binding
advisory vote, the shareholders also approved the aggregate amount of the
Management Committee's variable compensation for the business year 2016.
In his presentation to the shareholders at the meeting, Chief Executive Officer
Ronald Scott highlighted the achievement of the key company goals set for 2016.
He reported that the antifungal drug Cresemba(®) (isavuconazole) was launched
and is available to patients in key European markets. Additionally, Basilea
concluded development and commercialization partnerships for Cresemba and
Basilea's antibiotic Zevtera(®) (ceftobiprole) covering more than forty
countries. Moreover, Basilea entered into a contract in 2016 with the Biomedical
Advanced Research and Development Authority (BARDA) for the clinical phase 3
development of ceftobiprole. He explained that the total contract amount could
reach up to USD 100 million in non-dilutive funding.
Mr. Scott said: "Our first achievements in 2017 include the agreement of Special
Protocol Assessments with the US FDA for two ceftobiprole phase 3 studies. We
are now preparing to initiate these studies in bloodstream and skin infections
with the ultimate goal of gaining regulatory approval of ceftobiprole in the
United States."
In addition, he indicated that Basilea continues to focus on increasing the
sales of Cresemba and Zevtera, entering into additional collaborations to make
Cresemba and Zevtera available in further territories around the world, and
advancing its oncology compounds.
At the meeting, 31.5 percent of Basilea's share capital was represented.
Currently, 60.5 percent of the total shares outstanding are registered in
Basilea's share registry.
About Basilea
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products
that address the medical problem of increasing resistance and non-response to
current treatment options in the therapeutic areas of bacterial infections,
fungal infections and cancer. The company uses the integrated research,
development and commercial operations of its subsidiary Basilea Pharmaceutica
International Ltd. to discover, develop and commercialize innovative
pharmaceutical products to meet the medical needs of patients with serious and
life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in
Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional
information can be found at Basilea's website www.basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any forward-
looking statements contained herein as a result of new information, future
events or otherwise.
For further information, please contact:
+----------------------------------------------------+
| Peer Nils Schröder, PhD |
| Head Corporate Communications & Investor Relations |
| +41 61 606 1102 |
| media_relations(at)basilea.com |
| investor_relations(at)basilea.com |
+----------------------------------------------------+
This press release can be downloaded from www.basilea.com.
Press release (PDF):
http://hugin.info/134390/R/2099909/795850.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Basilea Pharmaceutica AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 27.04.2017 - 18:32 Uhr
Sprache: Deutsch
News-ID 538886
Anzahl Zeichen: 7285
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 248 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders"
steht unter der journalistisch-redaktionellen Verantwortung von
Basilea Pharmaceutica AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
